Johnson & Johnson says localised delivery of its FGFR inhibitor erdafitinib could provide the first targeted treatment for early‑stage bladder cancer.
Makary pushes for IRB reforms to catch China’s speedy trial starts
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with


